Amelia Barcellini1, Viviana Vitolo2, Lorenzo Cobianchi3,4, Andrea Peloso5,6, Alessandro Vanoli7, Alfredo Mirandola2, Angelica Facoetti2, Maria Rosaria Fiore2, Alberto Iannalfi2, Barbara Vischioni2, Francesco Cuccia8, Sara Ronchi2, Maria Bonora2, Giulia Riva2, Rachele Petrucci2, Emma D'Ippolito2, Francesca Dal Mas9,10, Lorenzo Preda2,3, Francesca Valvo2. 1. National Center of Oncological Hadrontherapy (Fondazione CNAO), Pavia, Italy Amelia.Barcellini@cnao.it. 2. National Center of Oncological Hadrontherapy (Fondazione CNAO), Pavia, Italy. 3. Department of Clinical-Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy. 4. General Surgery, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. 5. Division of Abdominal Surgery, Department of Surgery, Faculty of Medicine, University of Geneva, Geneva, Switzerland. 6. HepatoPancreato-Biliary Centre, Geneva University Hospitals, Geneva, Switzerland. 7. Anatomic Pathology Unit, Department of Molecular Medicine, University of Pavia and Fondazione IRCCS Policlinico San Matteo, Pavia, Italy. 8. School of Radiation Oncology, University of Palermo, Palermo, Italy. 9. Lincoln International Business School, University of Lincoln, Lincoln, U.K. 10. Department of Law and Economics of Productive Activities, Sapienza University of Rome, Rome, Italy.
Abstract
BACKGROUND/AIM: Re-irradiation of locally recurrent rectal cancer poses challenges due to the proximity of critical organs, such as the bowel. This study aimed at evaluating the safety and efficacy of re-irradiation with Carbon Ion Radiotherapy (CIRT) in rectal cancer patients with local recurrence. PATIENTS AND METHODS: Between 2014 and 2018, 14 patients were treated at the National Center of Oncological Hadrontherapy (CNAO Foundation) with CIRT for locally recurrent rectal cancer. RESULTS: All patients concluded the treatment. No G≥3 acute/late reaction nor pelvic infections were observed. The 1-year and 2-year local control rates were, 78% and 52%, respectively, and relapse occurred close to the bowel in 6 patients. The 1-year and 2-year overall survival rates were 100% and 76.2% each; while the 1-year and 2-year metastasis free survival rates were 64.3% and 43%. CONCLUSION: CIRT as re-irradiation for locally recurrent rectal cancer emerges as a safe and valid treatment with an acceptable rate of morbidity of surrounding healthy tissue. Copyright
BACKGROUND/AIM: Re-irradiation of locally recurrent rectal cancer poses challenges due to the proximity of critical organs, such as the bowel. This study aimed at evaluating the safety and efficacy of re-irradiation with Carbon Ion Radiotherapy (CIRT) in rectal cancerpatients with local recurrence. PATIENTS AND METHODS: Between 2014 and 2018, 14 patients were treated at the National Center of Oncological Hadrontherapy (CNAO Foundation) with CIRT for locally recurrent rectal cancer. RESULTS: All patients concluded the treatment. No G≥3 acute/late reaction nor pelvic infections were observed. The 1-year and 2-year local control rates were, 78% and 52%, respectively, and relapse occurred close to the bowel in 6 patients. The 1-year and 2-year overall survival rates were 100% and 76.2% each; while the 1-year and 2-year metastasis free survival rates were 64.3% and 43%. CONCLUSION: CIRT as re-irradiation for locally recurrent rectal cancer emerges as a safe and valid treatment with an acceptable rate of morbidity of surrounding healthy tissue. Copyright
Authors: Rolf Sauer; Heinz Becker; Werner Hohenberger; Claus Rödel; Christian Wittekind; Rainer Fietkau; Peter Martus; Jörg Tschmelitsch; Eva Hager; Clemens F Hess; Johann-H Karstens; Torsten Liersch; Heinz Schmidberger; Rudolf Raab Journal: N Engl J Med Date: 2004-10-21 Impact factor: 91.245
Authors: Amelia Barcellini; Viviana Vitolo; Angelica Facoetti; Piero Fossati; Lorenzo Preda; Maria Rosaria Fiore; Barbara Vischioni; Alberto Iannalfi; Maria Bonora; Sara Ronchi; Emma D'Ippolito; Rachele Petrucci; Gisela Viselner; Mario Ciocca; Francesca Valvo; Roberto Orecchia Journal: In Vivo Date: 2019 Mar-Apr Impact factor: 2.155
Authors: A Pella; M Riboldi; B Tagaste; D Bianculli; M Desplanques; G Fontana; P Cerveri; M Seregni; G Fattori; R Orecchia; G Baroni Journal: Technol Cancer Res Treat Date: 2013-11-04
Authors: Randa Tao; Chiaojung Jillian Tsai; Garrett Jensen; Cathy Eng; Scott Kopetz; Michael J Overman; John M Skibber; Miguel Rodriguez-Bigas; George J Chang; Yi-Qian Nancy You; Brian K Bednarski; Bruce D Minsky; Marc E Delclos; Eugene Koay; Sunil Krishnan; Christopher H Crane; Prajnan Das Journal: Radiother Oncol Date: 2017-01-03 Impact factor: 6.280
Authors: S Giordanengo; M A Garella; F Marchetto; F Bourhaleb; M Ciocca; A Mirandola; V Monaco; M A Hosseini; C Peroni; R Sacchi; R Cirio; M Donetti Journal: Med Phys Date: 2015-01 Impact factor: 4.071
Authors: Daniel Habermehl; Martin Wagner; Malte Ellerbrock; Markus W Büchler; Oliver Jäkel; Jürgen Debus; Stephanie E Combs Journal: Ann Surg Oncol Date: 2014-11-11 Impact factor: 5.344